Evidence map›Paper›PMID 28578431›Full record

ArticleScientific reports2017

Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients.

Antonella Torosantucci, Mario Tumbarello, Carla Bromuro, Paola Chiani, Brunella Posteraro, Maurizio Sanguinetti, Roberto Cauda, Antonio Cassone

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Serum Levels ofMicroorganisms · 2025
    Article
  2. Article
  3. Association of Antibody Immunity With Cryptococcal Antigenemia and Mortality in a South African Cohort With Advanced Human Immunodeficiency Virus Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  4. Review
  5. Article
  6. The Role ofFrontiers in cellular and infection microbiology · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Antonella TorosantucciDepartment of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy.
Mario TumbarelloInstitute of Infectious Diseases, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Carla BromuroDepartment of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy.
Paola ChianiDepartment of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy.
Brunella PosteraroInstitute of Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Maurizio SanguinettiInstitute of Microbiology, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Roberto CaudaInstitute of Infectious Diseases, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Antonio CassonePolo d'innovazione della genomica, genetica e biologia, University of Perugia, 71000, Perugia, Italy. a.cassone@pologgb.com.
Università Cattolica del Sacro Cuore · ITIstituto Superiore di Sanità · ITPolo d’Innovazione di Genomica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-Candida immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, FungalCandida albicansCandidiasisFemaleFungal ProteinsGlucansHumansImmunoglobulin GMaleMicrobial ViabilityMiddle AgedYoung AdultAntibodies, FungalFungal ProteinsGlucansImmunoglobulin G

Identifiers

PMID28578431
PMCPMC5457410
OpenAlexW2618437552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.